Scoop: Calling off an IPO, a cancer and Covid-19 vaccine maker raises a Series C

An oncology and Covid-19 biotech led by a former Flagship Pioneering venture partner is close to wrapping up its Series C after a bear market shut the doors to a planned IPO, Endpoints News has learned.

Elicio Therapeutics has secured $37 million of its planned $40 million Series C,...

Click to view original post